Acuta Capital Partners, LLC Amylyx Pharmaceuticals, Inc. Transaction History
Acuta Capital Partners, LLC
- $53.1 Million
- Q3 2025
A detailed history of Acuta Capital Partners, LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 333,258 shares of AMLX stock, worth $4.23 Million. This represents 8.53% of its overall portfolio holdings.
Number of Shares
333,258Holding current value
$4.23 Million% of portfolio
8.53%Shares
1 transactions
Others Institutions Holding AMLX
# of Institutions
183Shares Held
94.1MCall Options Held
421KPut Options Held
174K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...